Emerging research uncovers greater understanding of certain breast cancers
Published:
Tags:
WESTON, Fla. – An estimated 10% to 20% of breast cancers are known as “triple negative,” meaning they don’t respond to hormonal therapies and other medications.
While this can make triple negative breast cancer more deadly, Dr. Thomas Samuel, an oncologist with the Cleveland Clinic Weston, said a recent study found sub-types of the disease that respond differently to treatment.
“What this tells us is that if you have some of these certain sub-types, they may need less therapy than we would normally recommend. In other words, all triple negative breast cancers are not the same and they shouldn’t all be treated the same. There really should be a breakdown of what type of triple negative cancer it is and then tailor the treatment to that diagnosis,” he said.
Article content
Advocates across the country are calling on provincial governments to adjust COVID-19 vaccine prioritization so cancer patients receive their second dose within four weeks rather than waiting up to 16 weeks.
Concern over a delayed second dose comes from preliminary data out of the U.K. which found people with solid cancers (a physical tumour) and blood cancers had a much lower antibody response following just one dose of the Pfizer vaccine compared to healthy people. When a second booster was given 21 days later, nearly all solid cancer patients had a much higher antibody response. This means delaying a second dose could prevent patients from having a fuller response to the vaccine and leaves them susceptible to COVID-19 while they wait for their second jab.
Share this article
Share this article
ResearchAndMarkets.com s offering.
The Global Leukemia Therapeutics Market was valued USD18584.23 Million in 2020 and is expected to grow at a CAGR of 7.47% during the forecast period.
The Global Leukemia Therapeutics Market is driven by the technological advancements and innovations in the field of blood cancer testing on account of the growing number of patients suffering from leukemia. Additionally, growing awareness among the population pertaining to adoption of preventive healthcare is further expected to propel the market during forecast period. Supportive government initiatives and policies for promoting cancer awareness are anticipated to fuel the market growth until 2026.
Immuno-Oncology Drugs Industry Trends Involve Collaborations, Mergers, Acquisitions Among Market Players einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.
Cancer Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030
The Business Research Company’s Cancer Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030
LONDON, GREATER LONDON , UK, April 20, 2021 /EINPresswire.com/ Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports
The rise in the number of cancer cases across the globe is likely to contribute to the growth of the cancer monoclonal antibody therapy market. According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the USA. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all new cancer cases. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the cancer monoclonal antib